-
Je něco špatně v tomto záznamu ?
ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia
S. Sucha, A. Sorf, M. Svoren, D. Vagiannis, F. Ahmed, B. Visek, M. Ceckova
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- akutní myeloidní leukemie * farmakoterapie genetika metabolismus MeSH
- antracykliny farmakologie MeSH
- inhibitory proteinkinas farmakologie MeSH
- leukocyty mononukleární účinky léků metabolismus MeSH
- lidé MeSH
- mikro RNA * genetika metabolismus MeSH
- mutace MeSH
- P-glykoproteiny * genetika metabolismus MeSH
- staurosporin * analogy a deriváty farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Low curability of patients diagnosed with acute myeloid leukemia (AML) must be seen as a call for better understanding the disease's mechanisms and improving the treatment strategy. Therapeutic outcome of the crucial anthracycline-based induction therapy often can be compromised by a resistant phenotype associated with overexpression of ABCB1 transporters. Here, we evaluated clinical relevance of ABCB1 in a context of the FMS-like tyrosine kinase 3 (FLT3) inhibitor midostaurin in a set of 28 primary AML samples. ABCB1 gene expression was absolutely quantified, confirming its association with CD34 positivity, adverse cytogenetic risk, and unachieved complete remission (CR). Midostaurin, identified as an ABCB1 inhibitor, increased anthracycline accumulation in peripheral blood mononuclear cells (PBMC) of CD34+ AML patients and those not achieving CR. This effect was independent of FLT3 mutation, indicating even FLT3- AML patients might benefit from midostaurin therapy. In line with these data, midostaurin potentiated proapoptotic processes in ABCB1-overexpressing leukemic cells when combined with anthracyclines. Furthermore, we report a direct linkage of miR-9 to ABCB1 efflux activity in the PBMC and propose miR-9 as a useful prognostic marker in AML. Overall, we highlight the therapeutic value of midostaurin as more than just a FLT3 inhibitor, suggesting its maximal therapeutic outcomes might be very sensitive to proper timing and well-optimized dosage schemes based upon patient's characteristics, such as CD34 positivity and ABCB1 activity. Moreover, we suggest miR-9 as a predictive ABCB1-related biomarker that could be immensely helpful in identifying ABCB1-resistant AML phenotype to enable optimized therapeutic regimen and improved treatment outcome.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018104
- 003
- CZ-PrNML
- 005
- 20220804134546.0
- 007
- ta
- 008
- 220720s2022 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2022.112962 $2 doi
- 035 __
- $a (PubMed)35462331
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Sucha, Simona $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
- 245 10
- $a ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia / $c S. Sucha, A. Sorf, M. Svoren, D. Vagiannis, F. Ahmed, B. Visek, M. Ceckova
- 520 9_
- $a Low curability of patients diagnosed with acute myeloid leukemia (AML) must be seen as a call for better understanding the disease's mechanisms and improving the treatment strategy. Therapeutic outcome of the crucial anthracycline-based induction therapy often can be compromised by a resistant phenotype associated with overexpression of ABCB1 transporters. Here, we evaluated clinical relevance of ABCB1 in a context of the FMS-like tyrosine kinase 3 (FLT3) inhibitor midostaurin in a set of 28 primary AML samples. ABCB1 gene expression was absolutely quantified, confirming its association with CD34 positivity, adverse cytogenetic risk, and unachieved complete remission (CR). Midostaurin, identified as an ABCB1 inhibitor, increased anthracycline accumulation in peripheral blood mononuclear cells (PBMC) of CD34+ AML patients and those not achieving CR. This effect was independent of FLT3 mutation, indicating even FLT3- AML patients might benefit from midostaurin therapy. In line with these data, midostaurin potentiated proapoptotic processes in ABCB1-overexpressing leukemic cells when combined with anthracyclines. Furthermore, we report a direct linkage of miR-9 to ABCB1 efflux activity in the PBMC and propose miR-9 as a useful prognostic marker in AML. Overall, we highlight the therapeutic value of midostaurin as more than just a FLT3 inhibitor, suggesting its maximal therapeutic outcomes might be very sensitive to proper timing and well-optimized dosage schemes based upon patient's characteristics, such as CD34 positivity and ABCB1 activity. Moreover, we suggest miR-9 as a predictive ABCB1-related biomarker that could be immensely helpful in identifying ABCB1-resistant AML phenotype to enable optimized therapeutic regimen and improved treatment outcome.
- 650 12
- $a P-glykoproteiny $x genetika $x metabolismus $7 D018435
- 650 _2
- $a antracykliny $x farmakologie $7 D018943
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní myeloidní leukemie $x farmakoterapie $x genetika $x metabolismus $7 D015470
- 650 _2
- $a leukocyty mononukleární $x účinky léků $x metabolismus $7 D007963
- 650 12
- $a mikro RNA $x genetika $x metabolismus $7 D035683
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 650 12
- $a staurosporin $x analogy a deriváty $x farmakologie $7 D019311
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sorf, Ales $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
- 700 1_
- $a Svoren, Martin $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
- 700 1_
- $a Vagiannis, Dimitrios $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
- 700 1_
- $a Ahmed, Fahda $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
- 700 1_
- $a Visek, Benjamin $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Sokolska 581, 50005 Hradec Kralove, Czech Republic
- 700 1_
- $a Ceckova, Martina $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic. Electronic address: martina.ceckova@faf.cuni.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 150, č. - (2022), s. 112962
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35462331 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134540 $b ABA008
- 999 __
- $a ok $b bmc $g 1821934 $s 1169347
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 150 $c - $d 112962 $e 20220421 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20220720